AKT/mTOR substrate p70S6k is frequently phosphorylated in gallbladder cancer tissue and cell lines

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1373-1384

  Leal, Pamela ^a   Garcia, Patricia ^b   Sandoval, Alejandra ^a   Buchegger, Kurt ^a   Weber, Helga ^a   Tapia, Oscar ^a   Roa, Juan Carlos ^a,b  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

AKT; Cell line; Gallbladder cancer; Migration; mTOR inhibitor; p70s6k

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AZD 8055; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P70S6K; RAPAMYCIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER INHIBITION; CANCER TISSUE; CELL DIFFERENTIATION; CELL MIGRATION; CELL VIABILITY; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; DYSPLASIA; EARLY CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; ETHNICITY; GALLBLADDER CANCER; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; UPREGULATION;

EID: 84885236367     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S46897     Document Type: Article

References (59)

1. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51: 349-364.
2. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118: 1591-1602.
3. Kresl JJ, Schild SE, Henning GT, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:167-175.
4. Malik IA, Aziz Z, Zaidi SH, Sethuraman G. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol. 2003;26:174-177.
5. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15:168-181.
6. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362: 1273-1281.
7. Furuse J, Kasuga A, Takasu A, Kitamura H, Nagashima F. Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci. 2010;19:337-341.
8. Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci. 2012;19:326-336.
9. Marino D, Leone F, Cavalloni G, Cagnazzo C, Aglietta M. Biliary tract carcinomas: from chemotherapy to targeted therapy. Crit Rev Oncol Hematol. 2013;85:136-148.
10. Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a Phase II Consortium study. J Clin Oncol. 2010;28:3491-3497.
11. Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2study. Lancet Oncol. 2010;11:48-54.
12. Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102: 68-72.
13. Chiorean EG, Ramasubbaiah R, Yu M, et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17:13.
14. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, openlabel, randomised, phase 3study. Lancet Oncol. 2012;13:181-188.
15. Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2study. Lancet Oncol. 2010;11: 1142-1148.
16. Leal P, Garcia P, Sandoval A, et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gall-bladder adenocarcinoma. Arch Pathol Lab Med. 2013;137:552-557.
17. Wu Q, Kiguchi K, Kawamoto T, et al. Therapeutic effect of rapamy-cin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007;67:3794-3800.
18. ClinicalTrials.gov, a serive of the US National Institutes of Health. Available from: http://clinicaltrails.gov/ct2/home. Accessed January, 2013.
19. National Cancer Institute. MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated May 28, 2013]. Available from: http://clinicaltrials.gov/show/NCT01425879. NLM identifier: NCT01425879. Accessed August 28, 2013.
20. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009;2:pe24.
21. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319:1-7.
22. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des. 2010;16:34-44.
23. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-1945.
24. Hartmann B. p70S6 kinase phosphorylation for pharmacodynamic monitoring. Clin Chim Acta. 2012;413:1387-1390.
25. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23:5853-5857.
26. Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/ p70S6K1signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287:C281-C291.
27. Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 2003;310:1124-1132.
28. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18: 2262-2271.
29. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10:6779-6788.
30. Keck S, Glencer AC, Rugo HS. Everolimus and its role in hormoneresistant and trastuzumab-resistant metastatic breast cancer. Future Oncol. 2012;8:1383-1396.
31. Mabuchi S, Altomare DA, Cheung M, et al. RAD001inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13:4261-4270.
32. Tai S, Sun Y, Liu N, et al. Combination of RAD001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 2012;11: 1320-1331.
33. Houghton PJ. Everolimus. Clin Cancer Res. 2010;16:1368-1372.
34. Keniry M, Parsons R. mTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop. Cancer Discov. 2011;1:203-204.
35. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70:288-298.
36. Giubellino A, Bullova P, Nolting S, et al. Combined inhibition of mTORC1 and mTORC2signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology. 2013;154: 646-655.
37. Holt SV, Logie A, Davies BR, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res. 2012;72: 1804-1813.
38. Sini P, James D, Chresta C, Guichard S. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055induces autophagy and cell death in cancer cells. Autophagy. 2010;6: 553-554.
39. Garcia P, Leal P, Alvarez H, et al. Connective tissue growth factor immunohistochemical expression is associated with gallbladder cancer progression. Arch Pathol Lab Med. 2013;137:245-250.
40. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177:1647-1656.
41. Shousha S. Oestrogen receptor status of breast carcinoma: Allred/H score conversion table. Histopathology. 2008;53:346-347.
42. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589-3594.
43. Dai B, Kong YY, Ye DW, et al. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 2009;104: 1009-1016.
44. Egervari G, Mark A, Hajdu M, et al. Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein. Histochem Cell Biol. 2011;135:409-417.
45. Heinonen H, Nieminen A, Saarela M, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008;9:348.
46. Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 2007;120:1803-1810.
47. Miyakawa M, Tsushima T, Murakami H, et al. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J. 2003;50:77-83.
48. No JH, Jeon YT, Park IA, et al. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol. 2011;121:8-12.
49. Wang Z, Zheng T, Wu Q, Wang J, Wu C. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma. Neoplasma. 2012;59:137-141.
50. Xiao L, Wang YC, Li WS, Du Y. The role of mTOR and phosphop70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 2009;28:152.
51. Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor mediated invasion in human ovarian cancer cells. Endocrinology. 2006;147:2557-2566.
52. Dhar R, Basu A. Constitutive activation of p70S6 kinase is associated with intrinsic resistance to cisplatin. Int J Oncol. 2008;32: 1133-1137.
53. Kim EK, Kim HA, Koh JS, et al. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2011;126:93-99.
54. Liu LZ, Zhou XD, Qian G, et al. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007;67:6325-6332.
55. Lee D, Do IG, Choi K, et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2012;25:131-139.
56. Koyama S, Yoshioka T, Mizushima A, et al. Establishment of a cell line (G-415) from a human gallbladder carcinoma. Gann. 1980;71:574-575.
57. Ghosh M, Koike N, Yanagimoto G, et al. Establishment and characterization of unique human gallbladder cancer cell lines. Int J Oncol. 2004;24:1189-1196.
58. Ip CK, Cheung AN, Ngan HY, Wong AS. p70S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011;30:2420-2432.
59. Calvo et al. First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2012;30 Suppl:Abstr 3005.